Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMET for Ocular Surface Diseases
NCT03943797Phase 1Unknown
- Sponsor
- Chang Gung Memorial Hospital
- Start
- Mar 2016
- Primary completion
- Dec 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Ocuris in limbal stem cell deficiency (LSCD), sponsored by Chang Gung Memorial Hospital. Primary endpoint: Proportion of study specific Adverse Events at 12 months. Status: unknown.
02
Drugs
Ocuris
03
Conditions
limbal stem cell deficiency (LSCD)
Beyond the preview
Go deeper on NCT03943797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03943797.